Aankondiging • 3h
Vary Tech, Evonik and Supezet Launch Full-Chain Chemical Recycling Package for Waste Plastics to High-Quality Ppo and Circular Naphtha Vary Tech, a global leader in solid waste resource utilization, together with Evonik and SupeZET, officially launched a full-industry chain process package for chemically recycling waste plastics into high-quality Plastic Pyrolysis Oil (PPO) and circular naphtha. The core technology is Vary Tech's oxygen-free pyrolysis, developed over 20 years and six iterations. With a single-unit capacity of 150 tons/day and over 8,000 operating hours annually, it ensures high front-end stability. The PPO then enters Evonik's proprietary Rocket module for upgrading and impurity removal, followed by SupeZET's advanced hydrogenation and fractionation for deep refining. The complete chain — feedstock pretreatment, continuous pyrolysis, deep purification, and product offtake — directly outputs circular naphtha and high-quality PPO meeting international petrochemical standards. This ensures seamless entry into global petrochemical and low-carbon fuel supply chains, removing technical barriers to the high-end circular economy. As the core engine, Vary Tech's oxygen-free pyrolysis technology offers broad feedstock compatibility. Beyond waste plastics, it has been applied to waste tires, oil sludge, industrial hazardous waste, medical waste, and new energy solid waste, with over 100 commercial pyrolysis lines delivered globally. While building chemical recycling, Vary Tech also leads in mechanical recycling. Leveraging 16 years of self-operated plant experience and its "high-end equipment manufacturing + industrial operation" dual-drive model, Vary Tech showcased its AI-powered intelligent home appliance dismantling system at the exhibition. Achieving 200 units per hour — a global efficiency record — the system delivers high-purity separation of all e-waste categories. Vary Tech has empowered Haier, TCL, and Midea, providing green recycling services for over 130 million obsolete appliances worldwide. From mechanical to chemical recycling, Vary Tech is integrating global supply chain resources to deliver scalable, economical, and sustainable technical solutions for global climate action and circular economy goals. Reported Earnings • May 11
First quarter 2026 earnings released: EPS: €0.27 (vs €0.50 in 1Q 2025) First quarter 2026 results: EPS: €0.27 (down from €0.50 in 1Q 2025). Revenue: €3.43b (down 9.3% from 1Q 2025). Net income: €125.0m (down 46% from 1Q 2025). Profit margin: 3.6% (down from 6.2% in 1Q 2025). Revenue is forecast to grow 2.6% p.a. on average during the next 3 years, compared to a 3.6% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 70% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings. Live nieuws • May 07
Evonik Industries Stock Plunges 51% as Investors Await Crucial Earnings Report Evonik Industries stock dropped 50.8% intraday on 5 May, reflecting a sharp loss of confidence ahead of its upcoming earnings release.
The move highlights investor concern over profitability, operational headwinds and the resilience of the current dividend policy.
The 8 May earnings announcement is seen as a key test of management’s outlook and plans through 2026.
For you as an investor, the price shock signals that the market is bracing for potentially weak numbers or a reset in expectations, but without the earnings release yet, the exact triggers are not clear. The focus now is on whether management can provide a detailed picture of operational performance and explain how current conditions affect margins, cash flow and the dividend.
The 2026 guidance will be especially important because it should show how Evonik plans to position its portfolio and manage costs over the medium term. Pay close attention to any commentary on capital allocation, possible changes to the payout, and the balance between investment and balance-sheet protection. This earnings call is likely to set the tone for how the stock is viewed until there is more concrete financial information. Aankondiging • Apr 17
Evonik Industries AG, Annual General Meeting, Jun 03, 2026 Evonik Industries AG, Annual General Meeting, Jun 03, 2026, at 10:00 W. Europe Standard Time. Valuation Update With 7 Day Price Move • Mar 27
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to €16.28, the stock trades at a forward P/E ratio of 21x. Average forward P/E is 14x in the Chemicals industry in Germany. Total returns to shareholders of 1.3% over the past three years. New Risk • Mar 08
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 43% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Minor Risks Dividend is not well covered by earnings (176% payout ratio). Large one-off items impacting financial results. Declared Dividend • Feb 07
Dividend reduced to €1.00 Dividend of €1.00 is 15% lower than last year. Ex-date: 4th June 2026 Payment date: 8th June 2026 Dividend yield will be 6.7%, which is higher than the industry average of 6.1%. Sustainability & Growth Dividend is covered by both earnings (74% earnings payout ratio) and cash flows (67% cash payout ratio). The dividend has not increased over the past 10 years but has been stable with no material reductions to payments, indicating a long track record of dividend stability. EPS is expected to decline by 19% over the next 3 years. A fall of 18% would increase the payout ratio to a potentially unsustainable range, which means the dividend may be at risk. New Risk • Feb 06
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 5.3% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 5.3% per year for the foreseeable future. Minor Risks High level of debt (45% net debt to equity). Dividend is not well covered by earnings (dividend per share is over 5x earnings per share). Reported Earnings • Feb 06
Full year 2025 earnings: EPS misses analyst expectations Full year 2025 results: EPS: €1.36 (up from €0.48 in FY 2024). Revenue: €14.1b (down 7.2% from FY 2024). Net income: €634.0m (up 186% from FY 2024). Profit margin: 4.5% (up from 1.5% in FY 2024). The increase in margin was driven by lower expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 20%. Revenue is forecast to grow 2.2% p.a. on average during the next 3 years, compared to a 2.4% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 46% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings. Aankondiging • Feb 06
Evonik Industries AG announces Annual dividend, payable on June 08, 2026 Evonik Industries AG announced Annual dividend of EUR 1.0000 per share payable on June 08, 2026, ex-date on June 04, 2026 and record date on June 05, 2026. Price Target Changed • Nov 11
Price target decreased by 10% to €16.45 Down from €18.37, the current price target is an average from 13 analysts. New target price is 19% above last closing price of €13.80. Stock is down 23% over the past year. The company is forecast to post earnings per share of €0.76 for next year compared to €0.48 last year. Major Estimate Revision • Nov 11
Consensus EPS estimates fall by 23% The consensus outlook for fiscal year 2025 has been updated. 2025 EPS estimate fell from €0.994 to €0.761 per share. Revenue forecast steady at €14.0b. Net income forecast to grow 351% next year vs 33% growth forecast for Chemicals industry in Germany. Consensus price target down from €17.63 to €16.45. Share price fell 3.6% to €13.80 over the past week. New Risk • Nov 06
New minor risk - Financial position The company has a high level of debt. Net debt to equity ratio: 45% This is considered a minor risk. Having a high level of debt increases the company's balance sheet risk. The company has a higher interest repayment burden, leading to the need to allocate a greater amount of its earnings towards servicing the debt, potentially limiting growth options or shareholder distributions. It can also increase the risk of bankruptcy if business conditions deteriorate enough that the company can no longer meet its debt obligations. Currently, the following risks have been identified for the company: Major Risk Dividend is not well covered by earnings and cash flows. Dividend per share is over 5x earnings per share. Cash payout ratio: 120% Minor Risks High level of debt (45% net debt to equity). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (0.7% net profit margin). Reported Earnings • Nov 05
Third quarter 2025 earnings: EPS and revenues miss analyst expectations Third quarter 2025 results: €0.23 loss per share (down from €0.48 profit in 3Q 2024). Revenue: €3.39b (down 12% from 3Q 2024). Net loss: €106.0m (down 148% from profit in 3Q 2024). Revenue missed analyst estimates by 1.5%. Earnings per share (EPS) were also behind analyst expectations. Revenue is forecast to grow 1.8% p.a. on average during the next 3 years, compared to a 2.5% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 11% per year whereas the company’s share price has fallen by 8% per year. Aankondiging • Oct 06
Evonik Industries AG to Report Q4, 2025 Results on Mar 04, 2026 Evonik Industries AG announced that they will report Q4, 2025 results on Mar 04, 2026 Price Target Changed • Sep 26
Price target decreased by 7.0% to €18.91 Down from €20.34, the current price target is an average from 13 analysts. New target price is 29% above last closing price of €14.69. Stock is down 31% over the past year. The company is forecast to post earnings per share of €1.01 for next year compared to €0.48 last year. Aankondiging • Sep 26
Evonik Industries AG Provides Earnings Guidance for the Third Quarter of 2025 Evonik Industries AG provided earnings guidance for the third quarter of 2025. The company expects revenue to be around €3.4 billion in the third quarter of 2025, compared to €3.8 billion in third quarter of 2024. Reported Earnings • Aug 03
Second quarter 2025 earnings: EPS and revenues miss analyst expectations Second quarter 2025 results: EPS: €0.26 (up from €0.011 loss in 2Q 2024). Revenue: €3.50b (down 11% from 2Q 2024). Net income: €120.0m (up €125.0m from 2Q 2024). Profit margin: 3.4% (up from net loss in 2Q 2024). Revenue missed analyst estimates by 5.4%. Earnings per share (EPS) also missed analyst estimates by 31%. Revenue is forecast to grow 2.5% p.a. on average during the next 3 years, compared to a 3.4% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 35% per year but the company’s share price has only fallen by 8% per year, which means it has not declined as severely as earnings. Upcoming Dividend • May 22
Upcoming dividend of €1.17 per share Eligible shareholders must have bought the stock before 29 May 2025. Payment date: 03 June 2025. The company is paying out more than 100% of its profits but is generating plenty of cash to support the dividend. Trailing yield: 5.8%. Within top quartile of German dividend payers (4.4%). Higher than average of industry peers (3.9%). Reported Earnings • May 13
First quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behind First quarter 2025 results: EPS: €0.50 (up from €0.33 in 1Q 2024). Revenue: €3.78b (flat on 1Q 2024). Net income: €233.0m (up 49% from 1Q 2024). Profit margin: 6.2% (up from 4.1% in 1Q 2024). Revenue missed analyst estimates by 2.2%. Earnings per share (EPS) exceeded analyst estimates by 48%. Revenue is forecast to grow 2.8% p.a. on average during the next 3 years, compared to a 3.6% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 61% per year but the company’s share price has only fallen by 9% per year, which means it has not declined as severely as earnings. Declared Dividend • Mar 07
Dividend of €1.17 announced Dividend of €1.17 is the same as last year. Ex-date: 29th May 2025 Payment date: 2nd June 2025 Dividend yield will be 5.4%, which is lower than the industry average of 6.1%. Sustainability & Growth Dividend is not covered by earnings (246% earnings payout ratio). However, it is covered by cash flows (62% cash payout ratio). The dividend has increased by an average of 1.6% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. The company's earnings per share (EPS) would need to grow by 173% to bring the payout ratio under control. EPS is expected to grow by 158% over the next 3 years, which means the dividend may need to be reduced to reach a sustainable payout ratio. New Risk • Mar 06
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 0% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Minor Risks Dividend is not well covered by earnings (237% payout ratio). Large one-off items impacting financial results. Aankondiging • Mar 06
Evonik Industries AG announces Annual dividend, payable on June 02, 2025 Evonik Industries AG announced Annual dividend of EUR 1.1700 per share payable on June 02, 2025, ex-date on May 29, 2025 and record date on May 30, 2025. Reported Earnings • Mar 06
Full year 2024 earnings: EPS misses analyst expectations Full year 2024 results: EPS: €0.48 (up from €1.00 loss in FY 2023). Revenue: €15.2b (flat on FY 2023). Net income: €222.0m (up €687.0m from FY 2023). Profit margin: 1.5% (up from net loss in FY 2023). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 54%. Revenue is forecast to grow 2.7% p.a. on average during the next 3 years, compared to a 3.8% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 72 percentage points per year, which is a significant difference in performance. Reported Earnings • Nov 07
Third quarter 2024 earnings: EPS and revenues miss analyst expectations Third quarter 2024 results: EPS: €0.48 (up from €0.21 loss in 3Q 2023). Revenue: €3.83b (up 1.6% from 3Q 2023). Net income: €223.0m (up €319.0m from 3Q 2023). Profit margin: 5.8% (up from net loss in 3Q 2023). Revenue missed analyst estimates by 2.1%. Earnings per share (EPS) also missed analyst estimates by 12%. Revenue is forecast to grow 2.2% p.a. on average during the next 3 years, compared to a 4.3% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 70 percentage points per year, which is a significant difference in performance. Aankondiging • Sep 20
Evonik Industries AG to Report Q1, 2025 Results on May 12, 2025 Evonik Industries AG announced that they will report Q1, 2025 results on May 12, 2025 Reported Earnings • Aug 02
Second quarter 2024 earnings released: €0.01 loss per share (vs €0.58 loss in 2Q 2023) Second quarter 2024 results: €0.01 loss per share (improved from €0.58 loss in 2Q 2023). Revenue: €3.93b (up 1.1% from 2Q 2023). Net loss: €5.00m (loss narrowed 98% from 2Q 2023). Revenue is forecast to grow 2.8% p.a. on average during the next 3 years, compared to a 4.6% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 72 percentage points per year, which is a significant difference in performance. Upcoming Dividend • May 29
Upcoming dividend of €1.17 per share Eligible shareholders must have bought the stock before 05 June 2024. Payment date: 07 June 2024. The company is not currently making a profit but it is cash flow positive. Trailing yield: 5.8%. Within top quartile of German dividend payers (4.6%). Higher than average of industry peers (5.0%). Reported Earnings • May 09
First quarter 2024 earnings released: EPS: €0.33 (vs €0.10 in 1Q 2023) First quarter 2024 results: EPS: €0.33 (up from €0.10 in 1Q 2023). Revenue: €3.80b (down 5.2% from 1Q 2023). Net income: €156.0m (up 232% from 1Q 2023). Profit margin: 4.1% (up from 1.2% in 1Q 2023). Revenue is forecast to grow 2.4% p.a. on average during the next 3 years, compared to a 4.2% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 65 percentage points per year, which is a significant difference in performance. Reported Earnings • Mar 05
Full year 2023 earnings: EPS and revenues miss analyst expectations Full year 2023 results: €1.00 loss per share (down from €1.16 profit in FY 2022). Revenue: €15.3b (down 17% from FY 2022). Net loss: €465.0m (down 186% from profit in FY 2022). Revenue missed analyst estimates by 1.3%. Earnings per share (EPS) also missed analyst estimates by 42%. Revenue is forecast to grow 2.7% p.a. on average during the next 3 years, compared to a 3.4% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 60% per year but the company’s share price has only fallen by 17% per year, which means it has not declined as severely as earnings. Aankondiging • Mar 05
International Chemical Investors S.E. agreed to acquire Superabsorbents business of Evonik. International Chemical Investors S.E. agreed to acquire Superabsorbents business of Evonik on March 4, 2024. The business to be sold generated sales of €892 million in 2023, with adjusted EBITDA in the mid double-digit million euro range. The final transfer of the business is planned for mid-2024 following approval by the relevant competition authorities. Aankondiging • Jan 16
Lanxess Reportedly Seeks to Sell Polyurethane Ops LANXESS Aktiengesellschaft (XTRA:LXS) has initiated a process to sell its polyurethane business, which could be valued at between EUR 500 million (USD 547.2 million) and EUR 600 million, German paper Handelsblatt reported on January 15, 2024. The company has engaged Deutsche Bank to search for a buyer, Handelsblatt said, citing people familiar with the matter. Chemical companies such as Evonik Industries AG (XTRA:EVK), Stockmeier, or Plixxent, are considered possible interested parties. With the sale, Lanxess aims to completely exit the plastics market as the company has transformed into a producer of ingredients for food, cosmetics, and pharmaceuticals. Reported Earnings • Nov 08
Third quarter 2023 earnings released: €0.21 loss per share (vs €0.46 profit in 3Q 2022) Third quarter 2023 results: €0.21 loss per share (down from €0.46 profit in 3Q 2022). Revenue: €3.77b (down 23% from 3Q 2022). Net loss: €96.0m (down 145% from profit in 3Q 2022). Revenue is forecast to grow 3.6% p.a. on average during the next 3 years, compared to a 3.1% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 42% per year but the company’s share price has only fallen by 8% per year, which means it has not declined as severely as earnings. Reported Earnings • Aug 11
Second quarter 2023 earnings: EPS and revenues miss analyst expectations Second quarter 2023 results: €0.58 loss per share (down from €0.64 profit in 2Q 2022). Revenue: €3.89b (down 19% from 2Q 2022). Net loss: €270.0m (down 191% from profit in 2Q 2022). Revenue missed analyst estimates by 5.6%. Earnings per share (EPS) were also behind analyst expectations. Revenue is forecast to grow 2.0% p.a. on average during the next 3 years, compared to a 1.9% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 18% per year but the company’s share price has only fallen by 10% per year, which means it has not declined as severely as earnings. Aankondiging • Jul 12
Evonik Industries AG Revises Financial Guidance for the Full Year 2023 Evonik Industries AG revised financial guidance for the full year 2023. The sales outlook is adjusted to a range between EUR 14 billion and EUR 16 billion (previously: EUR 17 billion to EUR 19 billion). Major Estimate Revision • Jun 30
Consensus EPS estimates fall by 20% The consensus outlook for earnings per share (EPS) in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from €17.0b to €16.7b. EPS estimate also fell from €1.14 per share to €0.914 per share. Net income forecast to grow 78% next year vs 38% decline forecast for Chemicals industry in Germany. Consensus price target down from €22.59 to €21.82. Share price rose 4.6% to €17.43 over the past week. Aankondiging • Jun 09
RAG Stiftung Not in Hurry to Cut Evonik Stake RAG-Stiftung is not in a hurry to reduce its stake in chemicals firm Evonik Industries AG (XTRA:EVK) as the foundation is not under financial pressure, RAG chairman Bernd Toenjes said at a press conference as quotes by German paper Frankfurter Allgemeine Zeitung (FAZ). RAG Stiftung, which owns 54.9% in the chemicals company, plans to cut its stake to a blocking minority in the future. The shareholding may fall below the majority threshold soon. According to Toenjes, a convertible bond is due in 2024, providing an opportunity to reach 50% by the end of 2024. For the moment, Evonik remains one of the most important assets for RAG Stiftung. Upcoming Dividend • May 25
Upcoming dividend of €1.17 per share at 5.9% yield Eligible shareholders must have bought the stock before 01 June 2023. Payment date: 05 June 2023. The company is paying out more than 100% of its profits and is paying out 81% of its cash flow. Trailing yield: 5.9%. Within top quartile of German dividend payers (4.7%). In line with average of industry peers (5.7%). Major Estimate Revision • May 16
Consensus EPS estimates fall by 12% The consensus outlook for fiscal year 2023 has been updated. 2023 EPS estimate fell from €1.32 to €1.16 per share. Revenue forecast steady at €17.1b. Net income forecast to grow 117% next year vs 21% decline forecast for Chemicals industry in Germany. Consensus price target down from €23.28 to €22.64. Share price was steady at €19.14 over the past week. Reported Earnings • May 10
First quarter 2023 earnings: EPS and revenues miss analyst expectations First quarter 2023 results: EPS: €0.10 (down from €0.67 in 1Q 2022). Revenue: €4.01b (down 11% from 1Q 2022). Net income: €47.0m (down 85% from 1Q 2022). Profit margin: 1.2% (down from 7.0% in 1Q 2022). Revenue missed analyst estimates by 1.7%. Earnings per share (EPS) also missed analyst estimates by 15%. Revenue is forecast to grow 3.2% p.a. on average during the next 3 years, compared to a 3.0% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings.